Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158192 | 0.81 | PTGS2 (0.36) | CHRNA7KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5158439 | 0.76 | CHRNB4 (0.41) | CHRNA7NISCHALDH1A1MEN1KMT2A | |
| SCHEMBL5159848 | 0.75 | MEN1 (0.39) | MEN1KMT2ATSHRMAPK1 | |
| SCHEMBL5160157 | 0.75 | SLC6A3 (0.38) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL5159946 | 0.70 | KIF11 (0.40) | ALDH1A1TSHR | |
| SCHEMBL5158203 | 0.69 | GAA (0.35) | CHRNA7KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5158346 | 0.69 | TSHR (0.34) | ALDH1A1CYP2D6TSHRCYP2C19 | |
| SCHEMBL5160399 | 0.68 | KMT2A (0.35) | KDM4EALDH1A1MEN1KMT2ACYP2D6 | |
| SCHEMBL674996 | 0.67 | CHRNA7 (0.59) | CHRNA7KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6771883 | 0.67 | ESR1 (0.48) | CHRNA7KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | claimed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | disclosed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | ADRB3, BRD4, NAT1 | CHRNA7 818/4885NISCH 464/4885KDM4E 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.